Evidence Snapshot

Sodium-dependent dopamine transporter

CHEMBL338 SINGLE PROTEIN Rattus norvegicus

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:29:56Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 7:29 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL338

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Sodium-dependent dopamine transporter as ChEMBL target CHEMBL338, mapped to UniProt P23977. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Sodium-dependent dopamine transporter

SINGLE PROTEIN · Rattus norvegicus

As of 2026-09-13

ChEMBL target ID

CHEMBL338

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

P23977

Sodium-dependent dopamine transporter

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Sodium-dependent dopamine transporter matters

As of 2026-09-13

Sodium-dependent dopamine transporter is reviewed as Sodium-dependent dopamine transporter (UniProt P23977); the current evidence base includes 58 approved drugs, 3562 compounds, and 512 assays, with lead potency reaching pChEMBL 10.5.

Protein context

Sodium-dependent dopamine transporter

Sodium-dependent dopamine transporter Sequence length is 619 aa.

Review this target as Sodium-dependent dopamine transporter, mapped to UniProt P23977. Sequence length is 619 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt P23977 Protein

Disease context

Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Activity base

Portfolio and assay base

ChEMBL currently tracks 58 approved drugs, 3562 compounds, and 512 assays for this target. The dominant activity type is IC50. CHEMBL36720 is the current potency anchor at pChEMBL 10.5.

Use CHEMBL36720 as the tractability anchor when discussing potency (pChEMBL 10.5).

Activity source · ChEMBL 36 via Core Engine

58 approved pChEMBL 10.5

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Sodium-dependent dopamine transporter matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P23977, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

3562

Total Compounds

512

Total Assays

Approved Drugs

IC50: 2856.0, KI: 2590.0, EC50: 85.0, KD: 7.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL36720	10.5	IC50	—
No preferred name CHEMBL113621	10.4	Ki	—
No preferred name CHEMBL418190	10.4	IC50	—
No preferred name CHEMBL281594	10.2	Ki	Clinical
No preferred name CHEMBL168455	10.1	IC50	—

Approved Drugs

Structure	Compound	First Approval
	COCAINE CHEMBL370805	2017
	COCAINE HYDROCHLORIDE CHEMBL529437	2017
	DULOXETINE CHEMBL1175	2004
	ATOMOXETINE CHEMBL641	2002
	DEXMETHYLPHENIDATE CHEMBL827	2001
	DEXMETHYLPHENIDATE HYDROCHLORIDE CHEMBL904	2001
	VENLAFAXINE CHEMBL637	1993
	PAROXETINE CHEMBL490	1992
	PAROXETINE HYDROCHLORIDE CHEMBL6067650	1992
	SERTRALINE HYDROCHLORIDE CHEMBL1709	1991
	SERTRALINE CHEMBL809	1991
	CLOMIPRAMINE CHEMBL415	1989
	FLUOXETINE HYDROCHLORIDE CHEMBL1201082	1987
	BUPROPION CHEMBL894	1985
	NOMIFENSINE CHEMBL273575	1984
	DIPHENYLPYRALINE CHEMBL1492	1982
	DOPAMINE CHEMBL59	1974
	MAZINDOL CHEMBL781	1973
	METHYLPHENIDATE CHEMBL796	1955
	DEXTROAMPHETAMINE CHEMBL612	1955
	AMPHETAMINE CHEMBL405	1955
	BENZTROPINE CHEMBL1201203	1954
	MEPERIDINE HYDROCHLORIDE CHEMBL1701	1942
	AMINEPTINE CHEMBL418995	—

← Target Page

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:29:56Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 7:29 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL338